Darunavir is a protease inhibitor used with other HIV protease inhibitor drugs as well as ritonavir for the effective management of HIV-1 infection. As a second-generation protease inhibitor, darunavir is designed to combat resistance to standard HIV therapy. It was initially approved by the FDA in 2006.
...
Darunavir, co-administered with ritonavir, and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (HIV) in children age 3 or above and adults with HIV-1 infection.
Division of Infectious Diseases, University Hospital Basel, Basel, BS, Switzerland
Faculty of Medicine, Siriraj Hospital, Bangkok, Wanglang Road, Thailand
SEARCH, the Thai Red Cross AIDS Research Centre, Bangkok, Thailand
Josep Mallolas Masferrer, Barcelona, Spain
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Hôpital Saint Louis, Paris, France
GSK Investigational Site, San Antonio, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.